Prime Medicine

Prime Medicine develops gene editing therapies based on Prime Editing, a technology that enables the precise correction of genetic mutations at their source. The company focuses on treating genetic diseases by repairing DNA without making double-strand breaks, offering an alternative to traditional CRISPR approaches. Prime Editing is designed to target and correct a wide variety of mutations, allowing the development of therapeutic programs across multiple organ systems. Prime Medicine's pipeline includes investigational therapies for diseases affecting the liver, eye, blood, and central nervous system. The company integrates its proprietary delivery platforms and screening tools to enhance the specificity and durability of gene edits. Its research and development efforts aim to translate advances in genome editing into clinical applications with the potential for one-time, curative treatments.

Data last updated: June 2026